

OA'S CURRENT CONTRACTS:

AMGEN
800.447.1000

ASPEN CONSULTING GROUP LTD.
877.238.7032

AVENTIS
800.996.6626
(Reimbursement Hotline)

BEDFORD LABS
800.562.4797

GLAXOSMITHKLINE
888.825.5249

MEDICAL SPECIALITIES
800.967.6400

MEDIMMUNE ONCOLOGY, INC.
877.633.4411

MDINTOUCH
866.774.0002

MGI PHARMA
952.346.4700

NOVIDEA HEALTHCARE
877.503.1455

PHARMION
720.564.9100

ROCHE, INC.
973.235.5000

WYETH/GENETICS INSTITUTE
617.876.1170

NEW CONTRACT ANNOUNCEMENT:

MDinTouch

Oncology Associates is pleased to announce a new contract with MDinTouch effective October 9, 2002. MDinTouch offers a Web-based dictation, transcription and report distribution product.

BENEFITS OF THIS CONTRACT INCLUDE:

Online access to patient records, allowing for faster turnaround time; elimination of lost reports; elimination of tape pick-up/drop off; and the ability to use your own transcription company.

According to John Christopher, President of Oncology Associates, "Our partnership with MDinTouch will give members the opportunity to implement a more secure means of document exchange outside the walls of their practice and will simplify the medical transcription process. We are excited to provide this

value-added service to our members."

Kent Wreder, CEO and Founder of MDinTouch states, "As a new corporate partner, MDinTouch looks forward to assisting OA members in realizing significant cost reductions and achieving greater efficiency and productivity in the workflow process associated with dictation, transcription and report distribution. The platform of services offered through MDinTouch allows members to measure and manage this critical function."

For more information on implementing MDinTouch's product in your practice, please contact MDinTouch directly at 866-774-0002 or visit their web site at www.mdintouch.com.

See page 13 for more information.

ONCOLOGY ASSOCIATES SIGNS AGREEMENT WITH PHARMION FOR COST EFFECTIVE TREATMENT OF DVT IN CANCER PATIENTS

Oncology Associates has recently completed a pricing agreement with the Pharmion Corporation for Innohep® (tinzaparin sodium for injection). Innohep® is a once-daily low molecular weight heparin for the treatment of acute symptomatic deep vein thrombosis (DVT) with or without pulmonary embolism when administered in conjunction with warfarin sodium (such as Coumadin®). The product is currently approved in 55 countries and has been used for over 11 years to treat approximately 12 million patients worldwide.

Todd Houser, National Account Manager for Pharmion, stated, "We feel fortunate to have the opportunity to work with Oncology Associates. Our recent agreement for Innohep is just the beginning of what we (Pharmion) hope is a strong and growing relationship. As our oncology portfolio grows, we will be working with OA to partner with the clinicians to offer

the most clinically effective and cost effective care available."

DVT is a major complication in orthopedic, pelvic, abdominal and thoracic surgical patients, as well as those with other chronic diseases such as congestive heart failure, lung disease and diabetes. In addition, **cancer patients have an especially high risk of DVT**. Studies indicate that thrombosis is one of the most frequent complications and the second leading cause of death in patients with known cases of cancer.

For more information on Pharmion Corporation and their portfolio of products, visit their website at www.pharmion.com and for more information on Innohep® and for full prescribing information, visit www.innohepusa.com.

See page 16-19 for more information.

NDC#	Product Name	Strength	Package Size
67211-342-08	Innohep	20,000 IU per mL	2mL vial
67211-342-53	Innohep	20,000 IU per mL	10X2mL vial